Prometheus Laboratories Inc.

Prometheus Laboratories delivers precision-guided diagnostic solutions that empower you to provide optimized care for your gastroenterology and hepatology patients. Our comprehensive portfolio supports individualized patient management—from early disease detection to therapy selection and long-term monitoring—so you can make more informed clinical decisions and improve your patients’ outcomes.

We offer a robust portfolio of tests, including a continuum of innovative IBD tests that support achieving and maintaining patient remission, through personalized patient insights:

IBD Precis™: Obtain greater clarity to differentiate IBD from non-IBD and Crohn’s disease from ulcerative colitis with this next-generation serologic test. IBD Precis also provides insights on colonic involvement and risk of complications to support early diagnosis and risk stratification.

Respondr®: Helps identify your patient’s likelihood of response to infliximab, adalimumab or their biosimilars prior to the initiation of therapy. Respondr combines pre-therapy clearance and genetics to help you select the most appropriate treatment and build a management plan.

PredictrPK®: The only tests to guide personalized dosing optimization strategies for infliximab, adalimumab, vedolizumab, ustekinumab and their respective biosimilars. PredictrPK assesses individual pharmacokinetics to calculate drug clearance and estimated drug levels at alternative doses and/or intervals.

Anser®: Simultaneously measure serum drug levels and anti-drug antibodies for infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab and their respective biosimilars with our drug-tolerant therapeutic drug monitoring (TDM) tests using HMSA technology.

Liver Disease Monitoring:

FIBROSpect®: A simple, non-invasive blood test that aids in the detection, staging and monitoring of liver fibrosis with easy-to-read and interpret test results.